Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence SWOG S0337 randomized clinical trial

Edward M. Messing, Catherine M. Tangen, Seth P. Lerner, Deepak M. Sahasrabudhe, Theresa Koppie, David P. Wood, Philip C. Mack, Robert S. Svatek, Christopher P. Evans, Khaled S. Hafez, Daniel J. Culkin, Timothy C. Brand, Lawrence I. Karsh, Jeffrey M. Holzbeierlein, Shandra S. Wilson, Guan Wu, Melissa Plets, Nicholas J. Vogelzang, Ian M. Thompson

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

IMPORTANCE Low-grade non-muscle-invasive urothelial cancer frequently recurs after excision by transurethral resection of bladder tumor (TURBT). OBJECTIVE To determine whether immediate post-TURBT intravesical instillation of gemcitabine reduces recurrence of suspected low-grade non-muscle-invasive urothelial cancer compared with saline. DESIGN, SETTING, AND PARTICIPANTS Randomized double-blind clinical trial conducted at 23 US centers. Patients with suspected low-grade non-muscle-invasive urothelial cancer based on cystoscopic appearance without any high-grade or without more than 2 low-grade urothelial cancer episodes within 18 months before index TURBTwere enrolled between January 23, 2008, and August 14, 2012, and followed up every 3 months with cystoscopy and cytology for 2 years and then semiannually for 2 years. Patientswere monitored for tumor recurrence, progression to muscle invasion, survival, and toxic effects. The final date of follow-upwas August 14, 2016. INTERVENTIONS Participants were randomly assigned to receive intravesical instillation of gemcitabine (2 g in 100 mL of saline) (n = 201) or saline (100 mL) (n = 205) for 1 hour immediately following TURBT. MAIN OUTCOMES AND MEASURES The primary outcomewas time to recurrence of cancer. Secondary end points were time to muscle invasion and death due to any cause. RESULTS Among 406 randomized eligible patients (median age, 66 years; 84.7%men), 383 completed the trial. In the intention-To-Treat analysis, 67 of 201 patients (4-year estimate, 35%) in the gemcitabine group and 91 of 205 patients (4-year estimate, 47%) in the saline group had cancer recurrence within 4.0 years (hazard ratio, 0.66; 95%CI, 0.48-0.90; P<.001 by 1-sided log-rank test for time to recurrence). Among the 215 patients with low-grade non-muscle-invasive urothelial cancer who underwent TURBT and drug instillation, 34 of 102 patients (4-year estimate, 34%) in the gemcitabine group and 59 of 113 patients (4-year estimate, 54%) in the saline group had cancer recurrence (hazard ratio, 0.53; 95%CI, 0.35-0.81; P = .001 by 1-sided log-rank test for time to recurrence). Fifteen patients had tumors that progressed to muscle invasion (5 in the gemcitabine group and 10 in the saline group; P = .22 by 1-sided log-rank test) and 42 died of any cause (17 in the gemcitabine group and 25 in the saline group; P = .12 by 1-sided log-rank test). There were no grade 4 or 5 adverse events and no significant differences in adverse events of grade 3 or lower. CONCLUSIONS AND RELEVANCE Among patients with suspected low-grade non-muscle-invasive urothelial cancer, immediate postresection intravesical instillation of gemcitabine, compared with instillation of saline, significantly reduced the risk of recurrence over a median of 4.0 years. These findings support using this therapy, but further research is needed to compare gemcitabine with other intravesical agents.

Original languageEnglish (US)
Pages (from-to)1880-1888
Number of pages9
JournalJAMA - Journal of the American Medical Association
Volume319
Issue number18
DOIs
StatePublished - May 1 2018

Fingerprint

gemcitabine
Intravesical Administration
Urinary Bladder Neoplasms
Randomized Controlled Trials
Recurrence
Neoplasms
Muscles
Drug Instillation
Cystoscopy
Intention to Treat Analysis
Poisons

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence SWOG S0337 randomized clinical trial. / Messing, Edward M.; Tangen, Catherine M.; Lerner, Seth P.; Sahasrabudhe, Deepak M.; Koppie, Theresa; Wood, David P.; Mack, Philip C.; Svatek, Robert S.; Evans, Christopher P.; Hafez, Khaled S.; Culkin, Daniel J.; Brand, Timothy C.; Karsh, Lawrence I.; Holzbeierlein, Jeffrey M.; Wilson, Shandra S.; Wu, Guan; Plets, Melissa; Vogelzang, Nicholas J.; Thompson, Ian M.

In: JAMA - Journal of the American Medical Association, Vol. 319, No. 18, 01.05.2018, p. 1880-1888.

Research output: Contribution to journalArticle

Messing, EM, Tangen, CM, Lerner, SP, Sahasrabudhe, DM, Koppie, T, Wood, DP, Mack, PC, Svatek, RS, Evans, CP, Hafez, KS, Culkin, DJ, Brand, TC, Karsh, LI, Holzbeierlein, JM, Wilson, SS, Wu, G, Plets, M, Vogelzang, NJ & Thompson, IM 2018, 'Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence SWOG S0337 randomized clinical trial', JAMA - Journal of the American Medical Association, vol. 319, no. 18, pp. 1880-1888. https://doi.org/10.1001/jama.2018.4657
Messing, Edward M. ; Tangen, Catherine M. ; Lerner, Seth P. ; Sahasrabudhe, Deepak M. ; Koppie, Theresa ; Wood, David P. ; Mack, Philip C. ; Svatek, Robert S. ; Evans, Christopher P. ; Hafez, Khaled S. ; Culkin, Daniel J. ; Brand, Timothy C. ; Karsh, Lawrence I. ; Holzbeierlein, Jeffrey M. ; Wilson, Shandra S. ; Wu, Guan ; Plets, Melissa ; Vogelzang, Nicholas J. ; Thompson, Ian M. / Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence SWOG S0337 randomized clinical trial. In: JAMA - Journal of the American Medical Association. 2018 ; Vol. 319, No. 18. pp. 1880-1888.
@article{0d2325af8b6b48d0b95d4033257a8846,
title = "Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence SWOG S0337 randomized clinical trial",
abstract = "IMPORTANCE Low-grade non-muscle-invasive urothelial cancer frequently recurs after excision by transurethral resection of bladder tumor (TURBT). OBJECTIVE To determine whether immediate post-TURBT intravesical instillation of gemcitabine reduces recurrence of suspected low-grade non-muscle-invasive urothelial cancer compared with saline. DESIGN, SETTING, AND PARTICIPANTS Randomized double-blind clinical trial conducted at 23 US centers. Patients with suspected low-grade non-muscle-invasive urothelial cancer based on cystoscopic appearance without any high-grade or without more than 2 low-grade urothelial cancer episodes within 18 months before index TURBTwere enrolled between January 23, 2008, and August 14, 2012, and followed up every 3 months with cystoscopy and cytology for 2 years and then semiannually for 2 years. Patientswere monitored for tumor recurrence, progression to muscle invasion, survival, and toxic effects. The final date of follow-upwas August 14, 2016. INTERVENTIONS Participants were randomly assigned to receive intravesical instillation of gemcitabine (2 g in 100 mL of saline) (n = 201) or saline (100 mL) (n = 205) for 1 hour immediately following TURBT. MAIN OUTCOMES AND MEASURES The primary outcomewas time to recurrence of cancer. Secondary end points were time to muscle invasion and death due to any cause. RESULTS Among 406 randomized eligible patients (median age, 66 years; 84.7{\%}men), 383 completed the trial. In the intention-To-Treat analysis, 67 of 201 patients (4-year estimate, 35{\%}) in the gemcitabine group and 91 of 205 patients (4-year estimate, 47{\%}) in the saline group had cancer recurrence within 4.0 years (hazard ratio, 0.66; 95{\%}CI, 0.48-0.90; P<.001 by 1-sided log-rank test for time to recurrence). Among the 215 patients with low-grade non-muscle-invasive urothelial cancer who underwent TURBT and drug instillation, 34 of 102 patients (4-year estimate, 34{\%}) in the gemcitabine group and 59 of 113 patients (4-year estimate, 54{\%}) in the saline group had cancer recurrence (hazard ratio, 0.53; 95{\%}CI, 0.35-0.81; P = .001 by 1-sided log-rank test for time to recurrence). Fifteen patients had tumors that progressed to muscle invasion (5 in the gemcitabine group and 10 in the saline group; P = .22 by 1-sided log-rank test) and 42 died of any cause (17 in the gemcitabine group and 25 in the saline group; P = .12 by 1-sided log-rank test). There were no grade 4 or 5 adverse events and no significant differences in adverse events of grade 3 or lower. CONCLUSIONS AND RELEVANCE Among patients with suspected low-grade non-muscle-invasive urothelial cancer, immediate postresection intravesical instillation of gemcitabine, compared with instillation of saline, significantly reduced the risk of recurrence over a median of 4.0 years. These findings support using this therapy, but further research is needed to compare gemcitabine with other intravesical agents.",
author = "Messing, {Edward M.} and Tangen, {Catherine M.} and Lerner, {Seth P.} and Sahasrabudhe, {Deepak M.} and Theresa Koppie and Wood, {David P.} and Mack, {Philip C.} and Svatek, {Robert S.} and Evans, {Christopher P.} and Hafez, {Khaled S.} and Culkin, {Daniel J.} and Brand, {Timothy C.} and Karsh, {Lawrence I.} and Holzbeierlein, {Jeffrey M.} and Wilson, {Shandra S.} and Guan Wu and Melissa Plets and Vogelzang, {Nicholas J.} and Thompson, {Ian M.}",
year = "2018",
month = "5",
day = "1",
doi = "10.1001/jama.2018.4657",
language = "English (US)",
volume = "319",
pages = "1880--1888",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "18",

}

TY - JOUR

T1 - Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence SWOG S0337 randomized clinical trial

AU - Messing, Edward M.

AU - Tangen, Catherine M.

AU - Lerner, Seth P.

AU - Sahasrabudhe, Deepak M.

AU - Koppie, Theresa

AU - Wood, David P.

AU - Mack, Philip C.

AU - Svatek, Robert S.

AU - Evans, Christopher P.

AU - Hafez, Khaled S.

AU - Culkin, Daniel J.

AU - Brand, Timothy C.

AU - Karsh, Lawrence I.

AU - Holzbeierlein, Jeffrey M.

AU - Wilson, Shandra S.

AU - Wu, Guan

AU - Plets, Melissa

AU - Vogelzang, Nicholas J.

AU - Thompson, Ian M.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - IMPORTANCE Low-grade non-muscle-invasive urothelial cancer frequently recurs after excision by transurethral resection of bladder tumor (TURBT). OBJECTIVE To determine whether immediate post-TURBT intravesical instillation of gemcitabine reduces recurrence of suspected low-grade non-muscle-invasive urothelial cancer compared with saline. DESIGN, SETTING, AND PARTICIPANTS Randomized double-blind clinical trial conducted at 23 US centers. Patients with suspected low-grade non-muscle-invasive urothelial cancer based on cystoscopic appearance without any high-grade or without more than 2 low-grade urothelial cancer episodes within 18 months before index TURBTwere enrolled between January 23, 2008, and August 14, 2012, and followed up every 3 months with cystoscopy and cytology for 2 years and then semiannually for 2 years. Patientswere monitored for tumor recurrence, progression to muscle invasion, survival, and toxic effects. The final date of follow-upwas August 14, 2016. INTERVENTIONS Participants were randomly assigned to receive intravesical instillation of gemcitabine (2 g in 100 mL of saline) (n = 201) or saline (100 mL) (n = 205) for 1 hour immediately following TURBT. MAIN OUTCOMES AND MEASURES The primary outcomewas time to recurrence of cancer. Secondary end points were time to muscle invasion and death due to any cause. RESULTS Among 406 randomized eligible patients (median age, 66 years; 84.7%men), 383 completed the trial. In the intention-To-Treat analysis, 67 of 201 patients (4-year estimate, 35%) in the gemcitabine group and 91 of 205 patients (4-year estimate, 47%) in the saline group had cancer recurrence within 4.0 years (hazard ratio, 0.66; 95%CI, 0.48-0.90; P<.001 by 1-sided log-rank test for time to recurrence). Among the 215 patients with low-grade non-muscle-invasive urothelial cancer who underwent TURBT and drug instillation, 34 of 102 patients (4-year estimate, 34%) in the gemcitabine group and 59 of 113 patients (4-year estimate, 54%) in the saline group had cancer recurrence (hazard ratio, 0.53; 95%CI, 0.35-0.81; P = .001 by 1-sided log-rank test for time to recurrence). Fifteen patients had tumors that progressed to muscle invasion (5 in the gemcitabine group and 10 in the saline group; P = .22 by 1-sided log-rank test) and 42 died of any cause (17 in the gemcitabine group and 25 in the saline group; P = .12 by 1-sided log-rank test). There were no grade 4 or 5 adverse events and no significant differences in adverse events of grade 3 or lower. CONCLUSIONS AND RELEVANCE Among patients with suspected low-grade non-muscle-invasive urothelial cancer, immediate postresection intravesical instillation of gemcitabine, compared with instillation of saline, significantly reduced the risk of recurrence over a median of 4.0 years. These findings support using this therapy, but further research is needed to compare gemcitabine with other intravesical agents.

AB - IMPORTANCE Low-grade non-muscle-invasive urothelial cancer frequently recurs after excision by transurethral resection of bladder tumor (TURBT). OBJECTIVE To determine whether immediate post-TURBT intravesical instillation of gemcitabine reduces recurrence of suspected low-grade non-muscle-invasive urothelial cancer compared with saline. DESIGN, SETTING, AND PARTICIPANTS Randomized double-blind clinical trial conducted at 23 US centers. Patients with suspected low-grade non-muscle-invasive urothelial cancer based on cystoscopic appearance without any high-grade or without more than 2 low-grade urothelial cancer episodes within 18 months before index TURBTwere enrolled between January 23, 2008, and August 14, 2012, and followed up every 3 months with cystoscopy and cytology for 2 years and then semiannually for 2 years. Patientswere monitored for tumor recurrence, progression to muscle invasion, survival, and toxic effects. The final date of follow-upwas August 14, 2016. INTERVENTIONS Participants were randomly assigned to receive intravesical instillation of gemcitabine (2 g in 100 mL of saline) (n = 201) or saline (100 mL) (n = 205) for 1 hour immediately following TURBT. MAIN OUTCOMES AND MEASURES The primary outcomewas time to recurrence of cancer. Secondary end points were time to muscle invasion and death due to any cause. RESULTS Among 406 randomized eligible patients (median age, 66 years; 84.7%men), 383 completed the trial. In the intention-To-Treat analysis, 67 of 201 patients (4-year estimate, 35%) in the gemcitabine group and 91 of 205 patients (4-year estimate, 47%) in the saline group had cancer recurrence within 4.0 years (hazard ratio, 0.66; 95%CI, 0.48-0.90; P<.001 by 1-sided log-rank test for time to recurrence). Among the 215 patients with low-grade non-muscle-invasive urothelial cancer who underwent TURBT and drug instillation, 34 of 102 patients (4-year estimate, 34%) in the gemcitabine group and 59 of 113 patients (4-year estimate, 54%) in the saline group had cancer recurrence (hazard ratio, 0.53; 95%CI, 0.35-0.81; P = .001 by 1-sided log-rank test for time to recurrence). Fifteen patients had tumors that progressed to muscle invasion (5 in the gemcitabine group and 10 in the saline group; P = .22 by 1-sided log-rank test) and 42 died of any cause (17 in the gemcitabine group and 25 in the saline group; P = .12 by 1-sided log-rank test). There were no grade 4 or 5 adverse events and no significant differences in adverse events of grade 3 or lower. CONCLUSIONS AND RELEVANCE Among patients with suspected low-grade non-muscle-invasive urothelial cancer, immediate postresection intravesical instillation of gemcitabine, compared with instillation of saline, significantly reduced the risk of recurrence over a median of 4.0 years. These findings support using this therapy, but further research is needed to compare gemcitabine with other intravesical agents.

UR - http://www.scopus.com/inward/record.url?scp=85046788360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046788360&partnerID=8YFLogxK

U2 - 10.1001/jama.2018.4657

DO - 10.1001/jama.2018.4657

M3 - Article

C2 - 29801011

AN - SCOPUS:85046788360

VL - 319

SP - 1880

EP - 1888

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 18

ER -